Led intellectual property due diligence on behalf of Astellas Pharma (TSE:4503), Japan’s second largest pharmaceutical company by size, in its definitive agreement to acquire Audentes Therapeutics, Inc. (NASDAQ:BOLD), an, AAV-based genetic medicines company with a pipeline of product candidates including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM). The all-cash transaction is valued at approximately $3 billion, including the purchase of all common shares, options, restricted stock units, and other securities. The companies intend to combine their capabilities and resources to establish a leading position in the field of gene therapy.
McCarter & English, LLP | Contents of this website may contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.